ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

BLGO BioLargo Inc (QB)

0.33235
-0.033 (-9.03%)
30 Apr 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
BioLargo Inc (QB) USOTC:BLGO OTCMarkets Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.033 -9.03% 0.33235 0.325 0.3397 0.3628 0.33 0.3628 131,327 20:54:33

Statement of Changes in Beneficial Ownership (4)

02/04/2020 6:06pm

Edgar (US Regulatory)


FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5                       
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

CODE KENNETH REAY
2. Issuer Name and Ticker or Trading Symbol

BIOLARGO, INC. [ BLGO ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__X__ Director                    __X__ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Science Officer
(Last)          (First)          (Middle)

14921 CHESTNUT ST.
3. Date of Earliest Transaction (MM/DD/YYYY)

3/31/2020
(Street)

WESTMINSTER, CA 92683
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common stock 3/31/2020  A  366993 (3)A$0.17 (1)23755994 D (2) 

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares

Explanation of Responses:
(1) Shares received in exchange for a reduction in $62,389 owed by Issuer to Reporting Person for salary and unreimbursed business expenses.
(2) Aggregate total shares includes 22,139,012 shares owned indirectly by Reporting Person through a wholly owned corporation.
(3) The shares issued are unvested and subject to a Lock-Up Agreement dated as of the issuance date whereby shares vest only upon the earlier of (i) the sale of the Issuer of substantially all of its assets, (ii) the successful commercialization of Issuer's products or technologies as demonstrated by its receipt of at least $3,000,000 in cash, or the recognition of $3,000,000 in revenue, over a 12-month period from the sale of products and/or the license of technology; and (iii) the Company's breach of the employment agreement between the Company and Reporting Person and resulting in Reporting Person's termination.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
CODE KENNETH REAY
14921 CHESTNUT ST.
WESTMINSTER, CA 92683
XXChief Science Officer

Signatures
/s/ John R. Browning, Attorney-in-fact4/2/2020
**Signature of Reporting PersonDate

1 Year BioLargo (QB) Chart

1 Year BioLargo (QB) Chart

1 Month BioLargo (QB) Chart

1 Month BioLargo (QB) Chart

Your Recent History

Delayed Upgrade Clock